Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis

por Debled, M, Houédé, N, Madranges, N, Donamaria, C, Floquet, A, Durand, M, Mauriac, Louis
Publicado 2007

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

por Ray-Coquard, I, Favier, L, Weber, B, Roemer-Becuwe, C, Bougnoux, P, Fabbro, M, Floquet, A, Joly, F, Plantade, A, Paraiso, D, Pujade-Lauraine, E
Publicado 2013

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer

por MacGrogan, G, Rudolph, P, Mascarel, I de, Mauriac, L, Durand, M, Avril, A, Dilhuydy, J M, Robert, J, Mathoulin-Pélissier, S, Picot, V, Floquet, A, Sierankowski, G, Coindre, J M
Publicado 2003

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytored...

por Pautier, P., Floquet, A., Chevreau, C., Penel, N., Guillemet, C., Delcambre, C., Cupissol, D., Selle, F., Isambert, N., Piperno-Neumann, S., Saada-Bouzid, E., Bertucci, F., Bompas, E., Alexandre, J., Collard, O., Lebrun-Ly, V., Soulier, P., Toulmonde, M., Le Cesne, A., Lacas, B., Duffaud, F.
Publicado 2021

Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group

por Heudel, P-E, Fabbro, M, Roemer-Becuwe, C, Kaminsky, M C, Arnaud, A, Joly, F, Roche-Forestier, S, Meunier, J, Foa, C, You, B, Priou, F, Tazi, Y, Floquet, A, Selle, F, Berton-Rigaud, D, Lesoin, A, Kalbacher, E, Lortholary, A, Favier, L, Treilleux, I, Ray-Coquard, I
Publicado 2017